LAF237 for type 2 diabetes - horizon scanning review
NHSC
Record ID 32005000236
English
Authors' objectives:
This study aims to assess the effectiveness of LAF237 for type 2 diabetes.
Authors' recommendations:
LAF237 (Vildagliptin) belongs to the new class of incretin mimetic drugs. LAF237 is an oral treatment that in clinical trials is used in addition to, and as a substitute for, current glucose-lowering therapies in patients with type 2 diabetes. In a double-blind, placebo-controlled randomised phase II trial (published) in 107 patients with type 2 diabetes, LAF237 used as add-on therapy to metformin was associated with a reduction in glucose concentration that was sustained for one year. In a 12-week, double-blind, placebo-controlled trial (abstract) in 100 drug-naive patients with type 2 diabetes, LAF237 was associated with a reduction in fasting plasma glucose and 4-hour mean postprandial glucose levels. Numerous phase III studies are currently underway.
Authors' methods:
Overview
Details
Project Status:
Completed
Year Published:
2005
URL for published report:
http://www.hsric.nihr.ac.uk/search
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Diabetes Mellitus, Type 2
Contact
Organisation Name:
NIHR Horizon Scanning Centre
Contact Address:
The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
c.packer@bham.ac.uk
Contact Email:
c.packer@bham.ac.uk
Copyright:
National Horizon Scanning Centre (NHSC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.